Faecal Occult Blood testing

Mrs Sophie Barnes FRCPath

Consultant Clinical Scientist

Learning objectives

- Background
- Guidelines for colorectal cancer detection
- Tests available to detect occult blood in faeces
- Evidence for qFIT in symptomatic patients
- How to provide a service locally?

Colorectal cancer - Background

- 4th most common cancer
- 2nd most common cause of cancer death in UK
- 1st cause of cancer death in non-smoking males

Prognosis

- Bowel cancer is treatable & curable if detected early
- UK Screening detects 9 % cases 8% stage 4
- Symptomatic pathway 22 % stage 4
- 25 % detected through 2WW

NHS Bowel Cancer Screening

- 5 UK hubs since April 2006
- Biennial basis for 60-74 y olds
- On request > 75 y olds
- Moving to qFIT from April 2018



NHS Bowel Cancer Screening Programme

CRC detection: NG12, 2015

- 1.3 Lower gastrointestinal tract cancers Colorectal cancer
- 1.3.1 Refer people using a <u>suspected cancer pathway referral</u> (for an appointment within 2 weeks) for colorectal cancer if:
- they are aged 40 and over with <u>unexplained</u> weight loss and abdominal pain or
- they are aged 50 and over with unexplained rectal bleeding or
- they are aged 60 and over with:
- iron-deficiency anaemia or
- changes in their bowel habit, or
- tests show occult blood in their faeces (see recommendation 1.3.4 for who should be offered a test for occult blood in faeces). [new 2015]

CRC detection: NG12, 2015

Consider a suspected cancer pathway referral (for an appointment within 2 weeks) for colorectal cancer in

- 1.3.2 people with a rectal or abdominal mass. [new 2015]
- 1.3.3 adults aged under 50 with rectal bleeding **and** any of the following unexplained symptoms or findings:
- abdominal pain
- change in bowel habit
- weight loss
- iron-deficiency anaemia. [new 2015]


CRC detection: NG12, 2015

- 1.3.4 Offer testing for occult blood in faeces to assess for colorectal cancer in adults without rectal bleeding who:
- are aged 50 and over with unexplained:
 - abdominal pain or
 - weight loss, or
- are aged under 60 with:
 - changes in their bowel habit or
 - iron-deficiency anaemia, or
- are aged 60 and over and have anaemia even in the absence of iron deficiency.
- · [new 2015]

Faecal occult blood

- Blood in faeces invisible to naked eye
- Surrogate marker for bowel cancer


Detects Hb



Guaiac Faecal Occult Blood Test



Guaiacum officinale - Lignum Vitae







Guaiac Acid (Colourless)

$$+ H_2O_2$$

Oxidised Guaiac

gFOB at Charing Cross





Issues with guaiac FOBt

- Subjective detection of a blue colour
- False + : red meat, certain fruit/veg, NSAID, iron Rx
- False : vitamin C
- Poor diagnostic sensitivity and specificity for CRC
- False negatives not all cancers and pre-cancers will bleed
- FN rate as high as 50%

Faecal Immunochemical Testing

- Immunoassay for globin
- Quantitative
- 2 of 4 systems shown









Benefits of qFIT

- Globin is degraded by upper GI enzymes
- Highly specific for occult lower GI bleeding
- No diet or drug restrictions
- Higher sensitivity and specificity for CRC than gFOB
- Used for asymptomatic screening from April 2018

Issues with qFIT

- No EQA
- No independent IQC
- Stability?
- Hb variants α chain variants?
- Where does it fit in the pathway?



ORIGINAL ARTICLE

Gut 2016; 65:1463–1469

Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms

Craig Mowat, ¹ Jayne Digby, ² Judith A Strachan, ³ Robyn Wilson, ³ Francis A Carey, ⁴ Callum G Fraser, ² Robert J C Steele ²


- GPs prompted to request at referral
- OC-Sensor, 1043 qFIT
- If triaged to endoscopy < 6 weeks
- 755 paired qFIT and colonic investigations

Mowat Results - CRC detection

Taken from Mowat C, et al. Gut 2016; 65:1463–1469

FHb > 10 ug/g
 NPV 99.5 %

FHb detected
 NPV 100 %



Ian M. Godber*, Louise M. Todd, Callum G. Fraser, Linda R. MacDonald and Hakim Ben Younes

Use of a faecal immunochemical test for haemoglobin can aid in the investigation of patients with lower abdominal symptoms

- 999 consecutive patients referred from primary care for colonoscopy
- 507 qFIT by HM-JACKarc
- 484 diagnostic colonoscopy

Godber Results

- For CRC, HRA, IBD or colitis FHb > 10 ug/g NPV 96.2 %
- For CRC
 FHb > 10 ug/g
 NPV 100 %

AP&T Alimentary Pharmacology and Therapeutics

Aliment Pharmacol Ther 2017; 45: 354-363


Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients

M. M. Widlak*-†, C. L. Thomas‡, M. G. Thomas§, C. Tomkins‡, S. Smith¶, N. O'Connell*, S. Wurie*, L. Burns*, C. Harmston**, C. Evans**, C. U. Nwokolo*, B. Singh†† & R. P. Arasaradnam*-†-‡‡

- 2822 referred through 2WW pathway
- Approached 1364
- Recruited 799
- 430 paired qFIT and colonic investigations
- > 7μg Hb / g faeces positive (HM-JACKarc)

Widlak Results

For CRC & high grade dysplasia
 FHb > 7 ug/g
 NPV 99 %



No benefit gained by adding calprotectin

Taken from Widlak M, et al. Aliment Pharmacol Ther 2017; 45:354–363

Cancer Vanguards

- TWW referrals to complete qFIT
- Compare colonoscopy and FIT results with presenting symptoms, ethnicity and socioeconomic background etc
- Identify appropriate reference values and cut off points

NWLP

- Offer qFIT
- What is the appropriate cut-off? Rule out?
- What is the appropriate pathway for symptomatic patients? CCGs? Secondary care?
- Can it be used for surveillance?

If interested: sophiebarnes@nhs.net